belinostat

{
  "id": "MLC-T-ONC-000974",
  "term": "belinostat",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with peripheral T-cell lymphoma that has come back or has not gotten better with other treatment. It is also being studied in the treatment of other types of cancer. Belinostat blocks certain enzymes needed for cell division and may kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow and may help make cancer cells easier to kill with other anticancer drugs. It is a type of histone deacetylase inhibitor, a type of antiangiogenesis agent, and a type of chemosensitizer. Also called Beleodaq and PXD101.",
    "A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase."
  ],
  "synonyms": [
    "Beleodaq",
    "PXD101"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/belinostat/"
}